Precigen, Inc. (NASDAQ:PGEN) Director Randal J. Kirk acquired 206,004 shares of the stock in a transaction dated Monday, November 22nd. The shares were purchased at an average price of $3.59 per share, for a total transaction of $739,554.36. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
PGEN stock opened at $4.05 on Thursday. The company has a market capitalization of $837.29 million, a P/E ratio of -7.11 and a beta of 2.28. The company has a fifty day moving average price of $4.78 and a 200-day moving average price of $5.71. The company has a debt-to-equity ratio of 1.37, a quick ratio of 5.03 and a current ratio of 5.28. Precigen, Inc. has a 52-week low of $3.42 and a 52-week high of $11.10.
Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Monday, November 8th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Precigen had a negative net margin of 109.91% and a negative return on equity of 68.90%. As a group, sell-side analysts forecast that Precigen, Inc. will post -0.49 earnings per share for the current fiscal year.
Large investors have recently bought and sold shares of the company. New York State Teachers Retirement System acquired a new position in shares of Precigen in the 3rd quarter valued at about $4,281,000. Morgan Stanley acquired a new position in shares of Precigen in the 1st quarter valued at about $2,245,000. Third Security LLC lifted its stake in shares of Precigen by 0.7% in the 2nd quarter. Third Security LLC now owns 82,326,865 shares of the biotechnology company’s stock valued at $536,771,000 after purchasing an additional 566,388 shares during the period. Los Angeles Capital Management LLC acquired a new position in shares of Precigen in the 3rd quarter valued at about $2,595,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Precigen in the 3rd quarter valued at about $2,187,000. 68.97% of the stock is currently owned by institutional investors.
Precigen, Inc is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, Trans Ova and Human Biotherapeutics.
Featured Story: Quiet Period Expirations Explained
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.